Gilead Sciences (Nasdaq: GILD) has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
Data from Study 1489 and Study 1490 show the sustained efficacy and safety profile of Biktarvy, in the treatment of HIV-1 in treatment-naïve adults.
Presented at the 28th Conference on Retroviruses and Opportunistic Infections, the results also show that there was no treatment-emergent resistance for those treated with the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze